163 related articles for article (PubMed ID: 38085895)
41. Central nervous system involvement in T-cell lymphoma: A single center experience.
Gurion R; Mehta N; Migliacci JC; Zelenetz A; Moskowitz A; Lunning M; Moskowitz C; Hamlin P; Horwitz S
Acta Oncol; 2016 May; 55(5):561-6. PubMed ID: 27046135
[TBL] [Abstract][Full Text] [Related]
42. Diagnosis and management of primary central nervous system lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance.
Keane C; Hamad N; Barraclough A; Lee YY; Talaulikar D; Ku M; Wight J; Tatarczuch M; Swain F; Gregory GP
Intern Med J; 2022 Sep; 52(9):1624-1632. PubMed ID: 34927329
[TBL] [Abstract][Full Text] [Related]
43. Analysis of Key Factors Associated with Response to Salvage High-Dose Methotrexate Rechallenge in Primary Central Nervous System Lymphoma with First Relapse.
Du P; Chen H; Shen L; Liu X; Wu X; Chen L; Cao A; Geng D
Curr Oncol; 2022 Sep; 29(9):6642-6656. PubMed ID: 36135091
[TBL] [Abstract][Full Text] [Related]
44. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Ferreri AJ; Cwynarski K; Pulczynski E; Ponzoni M; Deckert M; Politi LS; Torri V; Fox CP; Rosée PL; Schorb E; Ambrosetti A; Roth A; Hemmaway C; Ferrari A; Linton KM; Rudà R; Binder M; Pukrop T; Balzarotti M; Fabbri A; Johnson P; Gørløv JS; Hess G; Panse J; Pisani F; Tucci A; Stilgenbauer S; Hertenstein B; Keller U; Krause SW; Levis A; Schmoll HJ; Cavalli F; Finke J; Reni M; Zucca E; Illerhaus G;
Lancet Haematol; 2016 May; 3(5):e217-27. PubMed ID: 27132696
[TBL] [Abstract][Full Text] [Related]
45. Primary central nervous system lymphoma - ocular variant: an interdisciplinary review on management.
Raval V; Binkley E; Aronow ME; Valenzuela J; Peereboom DM; Singh AD
Surv Ophthalmol; 2021; 66(6):1009-1020. PubMed ID: 33762182
[TBL] [Abstract][Full Text] [Related]
46. Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients.
Schorb E; Finke J; Ihorst G; Kasenda B; Fricker H; Illerhaus G
BMC Cancer; 2019 Mar; 19(1):287. PubMed ID: 30925912
[TBL] [Abstract][Full Text] [Related]
47. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.
Abramson JS; Hellmann M; Barnes JA; Hammerman P; Toomey C; Takvorian T; Muzikansky A; Hochberg EP
Cancer; 2010 Sep; 116(18):4283-90. PubMed ID: 20564149
[TBL] [Abstract][Full Text] [Related]
48. Primary and secondary central nervous system mature T- and NK-cell lymphomas.
Pang Y; Chihara D
Semin Hematol; 2021 Apr; 58(2):123-129. PubMed ID: 33906722
[TBL] [Abstract][Full Text] [Related]
49. Primary Central Nervous System Lymphoma.
Han CH; Batchelor TT
Continuum (Minneap Minn); 2017 Dec; 23(6, Neuro-oncology):1601-1618. PubMed ID: 29200113
[TBL] [Abstract][Full Text] [Related]
50. A single-center retrospective analysis of outcome measures and consolidation strategies for relapsed and refractory primary CNS lymphoma.
Bonm AV; Gibson AW; Holmberg LA; Mielcarek M; McGranahan T; Taylor LP; Graber JJ
J Neurooncol; 2021 Jan; 151(2):193-200. PubMed ID: 33398532
[TBL] [Abstract][Full Text] [Related]
51. A narrative review of consolidation strategies for young and fit patients with newly-diagnosed primary central nervous system lymphoma.
Steffanoni S; Calimeri T; Anzalone N; Mastaglio S; Bernardi M; Ferreri AJ
Expert Rev Hematol; 2022 Jan; 15(1):33-43. PubMed ID: 34904506
[TBL] [Abstract][Full Text] [Related]
52. Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma: A case report.
Yagi Y; Kanemasa Y; Ohigashi A; Morita Y; Tamura T; Nakamura S; Otsuka Y; Kishida Y; Kageyama A; Shimizuguchi T; Toya T; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Doki N; Okuyama Y; Omuro Y; Shimoyama T
Medicine (Baltimore); 2021 Nov; 100(44):e27733. PubMed ID: 34871273
[TBL] [Abstract][Full Text] [Related]
53. Treatment options for central nervous system lymphomas in immunocompetent patients.
Jahnke K; Thiel E
Expert Rev Neurother; 2009 Oct; 9(10):1497-509. PubMed ID: 19831839
[TBL] [Abstract][Full Text] [Related]
54. [Malignant lymphoma in the central nervous system: overview].
Namekawa M
Brain Nerve; 2014 Aug; 66(8):907-16. PubMed ID: 25082313
[TBL] [Abstract][Full Text] [Related]
55. Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy.
Al Feghali KA; Fang P; Gule-Monroe M; Milgrom S; Khoury JD; Gunther JR; Sheu T; Nair R; Ahmed S; Steiner R; Strati P; Shpall EJ; Nieto YL; Hosing C; Nastoupil LJ; Westin JR; Neelapu SS; Fowler N; Flowers C; Pinnix CC; Dabaja BS
Leuk Lymphoma; 2021 Oct; 62(10):2400-2407. PubMed ID: 33942701
[TBL] [Abstract][Full Text] [Related]
56. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.
El-Galaly TC; Cheah CY; Bendtsen MD; Nowakowski GS; Kansara R; Savage KJ; Connors JM; Sehn LH; Goldschmidt N; Shaulov A; Farooq U; Link BK; Ferreri AJM; Calimeri T; Cecchetti C; Dann EJ; Thompson CA; Inbar T; Maurer MJ; Gade IL; Juul MB; Hansen JW; Holmberg S; Larsen TS; Cordua S; Mikhaeel NG; Hutchings M; Seymour JF; Clausen MR; Smith D; Opat S; Gilbertson M; Thanarajasingam G; Villa D
Eur J Cancer; 2018 Apr; 93():57-68. PubMed ID: 29477102
[TBL] [Abstract][Full Text] [Related]
57. How I treat secondary CNS involvement by aggressive lymphomas.
Alderuccio JP; Nayak L; Cwynarski K
Blood; 2023 Nov; 142(21):1771-1783. PubMed ID: 37702537
[TBL] [Abstract][Full Text] [Related]
58. Central Nervous System Lymphoma.
Shah T; Venur VA
Semin Neurol; 2023 Dec; 43(6):825-832. PubMed ID: 37995744
[TBL] [Abstract][Full Text] [Related]
59. Primary Central Nervous System Lymphoma-PART 2: Modern Therapeutic Management and Future Directions.
Lukas RV; Gondi V; Stupp R; Raizer JJ
Oncology (Williston Park); 2018 Feb; 32(2):e11-e19. PubMed ID: 29492949
[TBL] [Abstract][Full Text] [Related]
60. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
Soussain C; Suzan F; Hoang-Xuan K; Cassoux N; Levy V; Azar N; Belanger C; Achour E; Ribrag V; Gerber S; Delattre JY; Leblond V
J Clin Oncol; 2001 Feb; 19(3):742-9. PubMed ID: 11157026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]